Patents by Inventor Thomas David McCarthy

Thomas David McCarthy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210374868
    Abstract: A system and method for real-time risk-assessment and adjustment, risks associated with a plurality of risk exposed individuals being at least partially transferable from a risk exposed individual to a first insurance system and/or from the first insurance system to an associated second insurance system. The system including a table with retrievable stored risk classes each comprising assigned risk class criteria, individual-specific parameters of the risk exposed individuals being captured relating to criteria of the stored risk classes by the system and stored in a memory, and a specific risk class associated with the risk of the exposed individual being identified out and selected of the stored risk classes by the system based on the captured parameters.
    Type: Application
    Filed: May 17, 2017
    Publication date: December 2, 2021
    Applicant: Swiss Reinsurance Company Ltd.
    Inventors: Thomas David MCCARTHY, William Edward MOORE, Michael Bruce CLARK, Jeffrey Stanton KATZ, Michael Wayne BERTSCHE, Edward Joseph WRIGHT, Anand KANAKAGIRI, Pratik DAVE, Janis PENNER
  • Patent number: 10370388
    Abstract: The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Grant
    Filed: February 6, 2017
    Date of Patent: August 6, 2019
    Assignee: NOVARTIS AG
    Inventors: Thomas David McCarthy, Alan Naylor
  • Patent number: 10308628
    Abstract: The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to compounds of formula (I), as described herein, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: June 4, 2019
    Assignee: NOVARTIS AG
    Inventors: Jane Brown, Thomas David McCarthy, Alan Naylor, John Paul Watts
  • Patent number: 10065943
    Abstract: The invention relates to heterocyclic angiotensin II type 2 (AT2) receptor antagonists of formula (I), and pharmaceutically acceptable salts thereof, ((I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, combinations thereof, and their use as medicaments, particularly for the treatment of neuropathic or inflammatory pain.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: September 4, 2018
    Assignee: Novartis AG
    Inventors: Jane Brown, Thomas David McCarthy, Alan Naylor, John Paul Watts
  • Publication number: 20180057477
    Abstract: The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to compounds of formula (I), as described herein, compositions containing them and their CM use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Application
    Filed: March 9, 2016
    Publication date: March 1, 2018
    Applicant: NOVARTIS AG
    Inventors: Jane BROWN, Thomas David MCCARTHY, Alan NAYLOR, John Paul WATTS
  • Publication number: 20170369473
    Abstract: The invention relates to heterocyclic angiotensin II type 2 (AT2) receptor antagonists of formula (I), and pharmaceutically acceptable salts thereof, ((I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof,combinations thereof, and their use as medic-aments, particularly for the treatment of neuropathic or inflammatory pain.
    Type: Application
    Filed: January 12, 2016
    Publication date: December 28, 2017
    Inventors: Jane BROWN, Thomas David MCCARTHY, Alan NAYLOR, John Paul WATTS
  • Publication number: 20170262940
    Abstract: A system and method for real-time risk-assessment and adjustment, risks associated with a plurality of risk exposed individuals being at least partially transferable from a risk exposed individual to a first insurance system and/or from the first insurance system to an associated second insurance system. The system including a table with retrievable stored risk classes each comprising assigned risk class criteria, individual-specific parameters of the risk exposed individuals being captured relating to criteria of the stored risk classes by the system and stored in a memory, and a specific risk class associated with the risk of the exposed individual being identified out and selected of the stored risk classes by the system based on the captured parameters.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 14, 2017
    Applicant: Swiss Reinsurance Company Ltd.
    Inventors: Thomas David MCCARTHY, William Edward MOORE, Michael Bruce CLARK, Jeffrey Stanton KATZ, Michael Wayne BERTSCHE, Edward Joseph WRIGHT, Anand KANAKAGIRI, Pratik DAVE, Janis PENNER
  • Patent number: 9714224
    Abstract: The present invention relates generally to compounds that are useful in antagonizing the angiotensin II type 2 (AT2) receptor. More particularly, the invention relates to substituted isoquinoline compounds and their use as AT2 receptor antagonists. Pharmaceutical compositions comprising the compounds and their use in modulating the AT2 receptor and therapies that require modulation of the AT2 receptor are described.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: July 25, 2017
    Assignee: NOVARTIS AG
    Inventors: Thomas David McCarthy, Alan Naylor
  • Patent number: 9708275
    Abstract: The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperazine and diazepine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: July 18, 2017
    Assignee: NOVARTIS AG
    Inventors: Thomas David McCarthy, Alan Naylor
  • Publication number: 20170145032
    Abstract: The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Application
    Filed: February 6, 2017
    Publication date: May 25, 2017
    Inventors: Thomas David MCCARTHY, Alan NAYLOR
  • Patent number: 9624234
    Abstract: The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: April 18, 2017
    Assignee: NOVARTIS AG
    Inventors: Thomas David McCarthy, Alan Naylor
  • Patent number: 9624243
    Abstract: The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: April 18, 2017
    Assignee: NOVARTIS AG
    Inventors: Thomas David McCarthy, Alan Naylor
  • Publication number: 20160257656
    Abstract: The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperazine and diazepine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Application
    Filed: May 9, 2016
    Publication date: September 8, 2016
    Inventors: Thomas David McCarthy, Alan Naylor
  • Publication number: 20160145213
    Abstract: The present invention relates generally to compounds that are useful in antagonizing the angiotensin II type 2 (AT2) receptor. More particularly, the invention relates to substituted isoquinoline compounds and their use as AT2 receptor antagonists. Pharmaceutical compositions comprising the compounds and their use in modulating the AT2 receptor and therapies that require modulation of the AT2 receptor are described.
    Type: Application
    Filed: July 8, 2014
    Publication date: May 26, 2016
    Inventors: Thomas David MCCARTHY, Alan NAYLOR
  • Patent number: 9162985
    Abstract: (S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: October 20, 2015
    Assignee: Spinifex Pharmaceuticals Pty Ltd
    Inventors: Thomas David McCarthy, Craig James Stewart Boyle, Alexander Redvers Eberlin, Peter Michael Kelly
  • Publication number: 20150218180
    Abstract: The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Application
    Filed: January 25, 2013
    Publication date: August 6, 2015
    Applicant: SPINIFEX PHARMACEUTICALS PTY LTD
    Inventors: Thomas David McCarthy, Alan Naylor
  • Patent number: 9095587
    Abstract: The present invention provides methods and compositions for the effective treatment of impaired nerve signal conduction. Compositions including selective AT2 receptor antagonists as active agents and methods of use in relation to improving nerve signal conduction or reversing impaired nerve signal conduction are described.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: August 4, 2015
    Assignee: Spinifex Pharmaceuticals Pty Ltd
    Inventors: Thomas David McCarthy, Nancy Hancock
  • Publication number: 20150105422
    Abstract: (S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described.
    Type: Application
    Filed: December 17, 2014
    Publication date: April 16, 2015
    Applicant: SPINIFEX PHARMACEUTICALS PTY LTD
    Inventors: Thomas David McCarthy, Craig James Stewart Boyle, Alexander Redvers Eberlin, Peter Michael Kelly
  • Publication number: 20150011565
    Abstract: The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to piperazine and diazepine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 8, 2015
    Inventors: Thomas David McCarthy, Alan Naylor
  • Patent number: 8927575
    Abstract: (S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: January 6, 2015
    Assignee: Spinifex Pharmaceuticals Pty Ltd
    Inventors: Thomas David McCarthy, Craig James Stewart Boyle, Alexander Redvers Eberlin, Peter Michael Kelly